Skip to main content

Press releases

Archive

7 May 2024

Topas Therapeutics Appoints Hugo Fry as CEO

25 May 2023

Topas Therapeutics Initiates Phase 2a Clinical Trial for TPM502 in Celiac Disease

15 February 2022

Topas Therapeutics Appoints Cristina de Min, M.D. as Chief Medical Officer

July 29, 2021

Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) in this Round

October 19, 2020

Topas Therapeutics Appoints Klaus Martin, Ph.D. as Chief Executive Officer

October 19, 2020

Topas Therapeutics Raises €22 Million (~USD 26 Million) in Series B Financing

December 18, 2019

Topas Therapeutics Announces First Patient Enrolled in Phase 1 Trial with TPM203 in Pemphigus Vulgaris

March 20, 2019

Topas Therapeutics to Participate at Upcoming Industry and Scientific Conferences

September 27, 2018

Topas Therapeutics to Participate at Upcoming Industry and Scientific Events

April 24, 2018

Topas Therapeutics and Boehringer Ingelheim Sign Multi-Year Collaboration and Option Agreement

January 25, 2018

Topas Therapeutics Serves as Exclusive Translational Partner for Collaborative Research Center Focused on Liver Inflammation at University Medical Center Hamburg-Eppendorf

November 2, 2017

Topas Therapeutics Extends its Series A to EUR 18 Million (USD 21 Million) with Boehringer Ingelheim Venture Fund

October 26, 2017

Topas Therapeutics Appoints Rupert Sandbrink, M.D., Ph.D., as Chief Development Officer and Chief Medical Officer

August 22, 2017

Topas Therapeutics Signs Multi-year Research and Option Agreement with Lilly Focused on Immune Tolerance

April 4, 2017

Paul Sekhri Joins Topas Therapeutics as Chairman of the Board

March 22, 2016

Evotec Spins Off Auto-immune Disease Company as ‘Topas Therapeutics GmbH’

March 22, 2016

Topas Therapeutics Raises EUR 14 Million to Treat Immunological Disorders